Nightstar Brings Tuyen Ong On Board as Chief Development Officer

Tuyen Ong is joining Nightstar as executive vice president and chief development officer. Ong comes to Nightstar from South Plainfield, NJ-based PTC Therapeutics (NASDAQ: [[ticker:PTCT]]), where we was chief medical officer. Ong will be based in Lexington, MA, where London-based Nightstar has its U.S. headquarters. The company, which develops treatments for rare congenital retinal diseases, is preparing for Phase 3 clinical trials testing its drug NSR-REP1 as a treatment for choroideremia, a condition characterized by a progressive loss of vision leading to complete blindness.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.